Amedisys (Nasdaq: AMED ) is expected to report Q4 earnings around Feb. 22. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Amedisys's revenues will grow 0.7% and EPS will decrease -55.1%.
The average estimate for revenue is $373.3 million. On the bottom line, the average EPS estimate is $0.22.
Last quarter, Amedisys logged revenue of $375.6 million. GAAP reported sales were 1.4% higher than the prior-year quarter's $370.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.33. GAAP EPS were $0.33 for Q3 versus -$14.73 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 43.0%, 240 basis points worse than the prior-year quarter. Operating margin was 3.9%, 130 basis points worse than the prior-year quarter. Net margin was 2.6%, 11,700 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.50 billion. The average EPS estimate is $1.00.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 816 members out of 902 rating the stock outperform, and 86 members rating it underperform. Among 230 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 200 give Amedisys a green thumbs-up, and 30 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $13.56.
Is Amedisys the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.